Pharmaceutical Investing Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam to Treat Moderate-to-Severe Acne
Carbonxt (CG1) Managing Director Warren Murphy at the Ignite Investment Summit, 26-27 March 2025 Hong Kong